Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type-Reference-Cited by-同舟云学术

Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type

Published:2023-12-15 Issue:50 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Nishimura Akira¹^ORCID,Yokoyama Kazuaki²,Naruto Takuya¹^ORCID,Yamagishi Chika¹^ORCID,Imamura Toshihiko³⁴^ORCID,Nakazono Hiroto¹,Kimura Shunsuke⁵^ORCID,Ito Mieko⁶,Sagisaka Maiko⁶,Tanaka Yukie⁷,Piao Jinhua¹^ORCID,Namikawa Yui¹,Yanagimachi Masakatsu⁶,Isoda Takeshi¹^ORCID,Kanai Akinori⁸^ORCID,Matsui Hirotaka⁹^ORCID,Isobe Tomoya¹⁰^ORCID,Sato-Otsubo Aiko¹⁰^ORCID,Higuchi Naoko¹¹,Takada Akiko¹²,Okuno Haruna¹³,Saito Shoji¹⁴^ORCID,Karakawa Shuhei¹⁵^ORCID,Kobayashi Shogo¹⁶^ORCID,Hasegawa Daisuke¹⁷^ORCID,Fujisaki Hiroyuki¹⁸^ORCID,Hasegawa Daiichiro¹⁹,Koike Kazutoshi²⁰,Koike Takashi²¹,Rai Shinya²²^ORCID,Umeda Katsutsugu¹²^ORCID,Sano Hideki¹⁶^ORCID,Sekinaka Yujin²³^ORCID,Ogawa Atsushi²⁴^ORCID,Kinoshita Akitoshi²⁵^ORCID,Shiba Norio²⁶^ORCID,Miki Mizuka²⁷,Kimura Fumihiko²⁸^ORCID,Nakayama Hideki²⁹,Nakazawa Yozo¹⁴^ORCID,Taga Takashi⁴³⁰^ORCID,Taki Tomohiko⁴³¹,Adachi Souichi⁴³²,Manabe Atsushi⁴³³,Koh Katsuyoshi⁴³⁴^ORCID,Ishida Yasushi⁴³⁵^ORCID,Takita Junko¹²^ORCID,Ishikawa Fumihiko³⁶³⁷^ORCID,Goto Hiroaki⁶^ORCID,Morio Tomohiro¹^ORCID,Mizutani Shuki¹^ORCID,Tojo Arinobu²³⁸^ORCID,Takagi Masatoshi¹⁴^ORCID

Affiliation:

1. Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

2. Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

3. Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

4. Leukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.

5. Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.

6. Division of Hematology/Oncology, Kanagawa Children’s Medical Center, Yokohama, Japan.

7. Research Core, Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

8. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

9. Department of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

10. Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan .

11. Department of Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan.

12. Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

13. Department of Pediatrics, Gunma University Hospital, Maebashi, Japan.

14. Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.

15. Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

16. Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

17. Department of Pediatrics, St. Luke’s International Hospital, Tokyo, Japan.

18. Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.

19. Department of Hematology and Oncology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan.

20. Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Mito, Japan.

21. Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.

22. Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.

23. Department of Pediatrics, National Defense Medical College, Tokorozawa, Japan.

24. Department of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan.

25. Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.

26. Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

27. Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.

28. Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.

29. Department of Pediatrics, Kyushu Cancer Center, Fukuoka, Japan.

30. Department of Pediatrics, Shiga University of Medical Science, Ohtsu, Japan.

31. Department of Medical Technology, Faculty of Health Sciences, Kyorin University, Tokyo, Japan.

32. Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

33. Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

34. Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan.

35. Pediatric Medical Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.

36. Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

37. Department of Comprehensive Pathology, Tokyo Medical and Dental University University (TMDU), Tokyo, Japan.

38. Data Science and Faculty Affairs, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Abstract

Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) has been described on the basis of its unique immunophenotype and clinical phenotype. However, there is no consensus on the characteristics for identifying this disease type because of its rarity and lack of defined distinctive molecular characteristics. In this study, multiomics analysis revealed that MNKPL is distinct from acute myeloid leukemia, T cell acute lymphoblastic leukemia, and mixed-phenotype acute leukemia (MPAL), and NOTCH1 and RUNX3 activation and BCL11B down-regulation are hallmarks of MNKPL. Although NK cells have been classically considered to be lymphoid lineage–derived, the results of our single-cell analysis using MNKPL cells suggest that NK cells and myeloid cells share common progenitor cells. Treatment outcomes for MNKPL are unsatisfactory, even when hematopoietic cell transplantation is performed. Multiomics analysis and in vitro drug sensitivity assays revealed increased sensitivity to l -asparaginase and reduced levels of asparagine synthetase (ASNS), supporting the clinically observed effectiveness of l -asparaginase.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adj4407

Reference54 articles.

1. CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity

2. Hematopoietic cell transplantation for myeloid/NK cell precursor acute leukemia in second remission

3. Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review

4. Natural killer cell neoplasms

5. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3 [see comments]